Vivek Subbiah: Sotorasib led to clinical improvement in disabling vascular malformations
shared a post on LinkedIn about a recent paper titled “Sotorasib for Vascular Malformations Associated with KRAS G12C Mutation” published in The New England Journal of Medicine.
Authors: Antoine Fraissenon, Charles Bayard, Gabriel Morin, Sandro Benichi, Clément Hoguin, Sanela Protic, Lola Zerbib, Sophia Ladraa, Marina Firpion, Thomas Blauwblomme, Olivier Naggara, Michael Duruisseaux, Marion Delous, Clothilde Boitel, Pierre-Paul Bringuier, Léa Payen, Christophe Legendre, Sophie Kaltenbach, Estelle Balducci, Patrick Villarese, Vahid Asnafi, Annouk Bisdorff, Laurent Guibaud and Guillaume Canaud.
“Wow! Precision Medicine in action – Sotorasib led to clinical improvement in two patients with disabling vascular malformations driven by the KRAS mutation G12C. Read the full report in The New England Journal of Medicine.
Cool bench to bedside work and drug repositioning.
2 mouse models of KRAS-vascular malformations and translation in humans.” 
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.